Cent Eur J Public Health 2022, 30(1):46-50 | DOI: 10.21101/cejph.a6885

Real-life experience in the effectiveness, impact on quality of life and safety of dupilumab treatment in patients with moderate to severe atopic dermatitis in the Czech Republic

Milena Tánczosová1, Martina Kojanová2, Monika Arenbergerová1, Petr Arenberger1, Tomáš Doležal3, Daniela Štrosová3, Jorga Fialová2, Spyridon Gkalpakiotis1
1 Department of Dermatovenereology, Charles University, Third Faculty of Medicine and University Hospital of Královské Vinohrady, Prague, Czech Republic
2 Department of Dermatovenereology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic
3 Value Outcomes, Prague, Czech Republic

Objectives: The aim of the study was to assess the effectiveness and safety of dupilumab therapy in patients with moderate-to-severe atopic dermatitis (AD) in a real-life Czech bicentric cohort.

Methods: We retrospectively analysed 50 patients with moderate-to-severe AD treated with dupilumab in two centres in the Czech Republic. Baseline characteristics, the Eczema Area and Severity Index (EASI) score and Dermatology Life Quality Index (DLQI) were collected at baseline and each 3 following months. The proportion of patients achieving EASI50, EASI75, EASI90 and EASI100 were analysed. Levels of immunoglobulin E (IgE) were collected before and after 6 and 12 months of therapy. Adverse events were recorded as well.

Results: Thirty-two men and 18 women with mean body mass index (BMI) of 25.7 were enrolled in our analysis. The mean age of the patients was 37.6 years and the mean time from diagnosis until the initiation of dupilumab therapy was 35.0 years. After 4 months, EASI75 was achieved by 75.7%, out of which 40.5% achieved EASI90 and 10.8% achieved complete clearance. Improvement continued with time, and the proportion of patients with EASI90 increased to 71.4% at the 6th month and at the 12th month of therapy the EASI90 was 65.2%. EASI100 was achieved by 14.3% and 13.0% at the 6th and 12th month, respectively. A marked reduction was observed in the DLQI and also in IgE levels. EASI responses were independent of BMI. No new safety issues were identified. Adverse events were experienced by 44% (22/50) of the patients and they were all mild in intensity. Conjunctivitis and herpes simplex virus infection were the most common adverse events.

Conclusion: Our results confirmed the effectiveness and safety of dupilumab in a real-life setting in adult patients with moderate-to-severe AD in the Czech Republic. Dupilumab was well-tolerated and resulted in a significant clinical improvement in combination with improvement of quality of life.

Keywords: atopic dermatitis, dupilumab, biological treatment, real-life, conjunctivitis

Received: April 20, 2021; Revised: January 12, 2022; Accepted: January 12, 2022; Published: March 31, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Tánczosová M, Kojanová M, Arenbergerová M, Arenberger P, Doležal T, Štrosová D, et al.. Real-life experience in the effectiveness, impact on quality of life and safety of dupilumab treatment in patients with moderate to severe atopic dermatitis in the Czech Republic. Cent Eur J Public Health. 2022;30(1):46-50. doi: 10.21101/cejph.a6885. PubMed PMID: 35421298.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Nutten S. Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metab. 2015;66 Suppl 1:8-16. Go to original source... Go to PubMed...
    2. Kanwar AJ. Adult-onset atopic dermatitis. Indian J Dermatol. 2016;61(6):662-3. Go to original source... Go to PubMed...
    3. Kim BS. Atopic dermatitis [Internet]. Medscape; 2022 [cited 2022 Jan 12]. Available from: https://emedicine.medscape.com/article/1049085-overview#a5.
    4. Ariëns LFM, Bakker DS, van der Schaft J, Garritsen FM, This JL, de Bruin-Weller MS. Dupilumab in atopic dermatitis: rationale, latest evidence and place in therapy. Ther Adv Chronic Dis. 2018; 9(9):159-70. Go to original source... Go to PubMed...
    5. Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, Deleuran M, Fink-Wagner A, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018; 32(5):657-82. Go to original source... Go to PubMed...
    6. Seegräber M, Srour J, Walter A, Knop M, Wollenberg A. Dupilumab for treatment of atopic dermatitis. Expert Rev Clin Pharmacol. 2018;11(5):467-74. Go to original source... Go to PubMed...
    7. Halling AS, Loft N, Silverberg JI, Guttman-Yassky E, Thyssen JP. Real-world evidence of dupilumab efficacy and risk of adverse events: a systematic review and meta-analysis. J Am Acad Dermatol. 2021;84(1):139-47. Go to original source... Go to PubMed...
    8. Faiz S, Giovannelli, J, Podevin, C, Jachiet, M, Bouaziz, JD, Reguiai Z, et al. Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort. J Am Acad Dermatol. 2019;81(1):143-51. Go to original source... Go to PubMed...
    9. Fargnoli MC, Esposito M, Ferrucci S, Girolomoni G, Offidani A, Patrizi A, et al. Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis. J Dermatol Treat. 2021;32(5):507-13. Go to original source... Go to PubMed...
    10. Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335-48. Go to original source... Go to PubMed...
    11. Annex 1. Summary of product characteristics [Internet]. [cited 2022 12 Jan ]. Available from: https://www.ema.europa.eu/en/documents/product-information/dupixent-epar-product-information_cs.pdf.
    12. Akinlade B, Guttman-Yassky E, de Bruin-Weller M, Simpson EL, Blauvelt A, Cork MJ, et al. Conjunctivitis in dupilumab clinical trials. Br J Dermatol. 2019;181(3):459-73. Go to original source...
    13. Punnonen J, Yssel H, de Vries J. The relative contribution of IL-4 and IL-13 to human IgE synthesis induced by activated CD4+ or CD8+ T cells. J Allergy Clin Immunol. 1997;100(6):792-801. Go to original source... Go to PubMed...

    Return to the content